UBS has recently initiated Myriad Genetics Inc (MYGN) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 9, 2024, Leerink Partners had reduced the ...
The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to the Vanderbilt University Medical Center study ...
Researchers from the Genome Center have successfully applied advanced artificial intelligence (AI) genetics models to Parkinson's disease. Researchers identified genetic factors in progression and ...